Peripheral blood IRF1 expression as a marker for glucocorticoid sensitivity

Area of Science:

• Genomics and Molecular Biology
• Asthma Pathophysiology
• Pharmacogenomics

Background:

• Glucocorticoids (GCs) are widely used for asthma, but many patients show GC insensitivity.
• Genomic factors, particularly gene expression changes, may underlie this insensitivity.
• Peripheral blood gene expression may mirror airway responses to GCs.

Purpose of the Study:

• To identify genes whose expression changes in response to GCs.
• To evaluate if these expression changes in peripheral blood can predict GC response in the airway.

Main Methods:

• In silico analysis of Gene Expression Omnibus (GEO) data to find GC-affected genes.
• Validation of candidate genes in human airway and blood cell lines and primary cells.
• Comparison of Interferon Regulator Factor 1 (IRF1) with NFKB1 as a control gene.

Main Results:

• Interferon Regulator Factor 1 (IRF1) expression was significantly downregulated by GC treatment across multiple cell types, including airway epithelial cells and lymphoblastoid cell lines.
• Significant interindividual variability in GC-induced IRF1 expression changes was observed in primary cells and peripheral blood mononuclear cells.
• IRF1 demonstrated more consistent downregulation across tissues compared to the control gene NFKB1.

Conclusions:

• GC-induced IRF1 gene expression changes in peripheral blood are a potential biomarker for predicting GC response in asthma.
• This finding could lead to personalized medicine approaches for asthma management.